Arecor Therapeutics (LON:AREC) Trading Down 0.3% – Here’s What Happened

Shares of Arecor Therapeutics plc (LON:AREC) fell 0.3% during trading on Thursday . The stock traded as low as GBX 85.26 and last traded at GBX 85.26. Approximately 1,182 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 24,282 shares. The stock had previously closed at GBX 85.50.

Arecor Therapeutics Trading Down 3.5%

The firm has a market capitalization of £31.34 million, a price-to-earnings ratio of 41.50 and a beta of -0.18. The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52. The company has a fifty day moving average price of GBX 68.05 and a two-hundred day moving average price of GBX 67.21.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.